Here we describe the effects of NX-1607, an orally bioavailable intramolecular glue inhibitor of CBL-B, on primary human T and NK cells and assess NX-1607 in combination with Rituximab …
Our analysis revealed that CT26 tumors from mice treated with NX-1607 exhibited significant changes in the immune cell density score and gene expression pathways related to innate and …
A First-in-Human Phase 1 Trial of NX-1607, a First-in
2023年11月2日 · NX-1607 is an oral, small molecule inhibitor of CBL-B that has been shown to enhance antigen recall, reduce T cell exhaustion and increase cytokine production upon T cell …
明星蛋白降解公司Nurix：首次公开同类首创CBL-B抑制剂NX-1607 …
2024年3月21日 · NX-1607是第一个进入临床阶段的CBL-B 抑制剂，目前正在进行一项人体、多中心、开放标签、1a/1b 期剂量递增/扩展试验，以评估药物的安全性、耐受性 ...
A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral …
2023年11月2日 · NX-1607 is an oral, small molecule inhibitor of CBL-B that has been shown to enhance antigen recall, reduce T cell exhaustion and increase cytokine production upon T cell …
First in class的 RING E3 连接酶(CBL-B)抑制剂筛选与设计 - 知乎
分享首款 RING E3 连接酶催化抑制剂NX-1607发现过程。 NX-1607通过锁定分子在非活性状态，以 分子内分子胶 (Intramolecular Glue)的机制抑制CBL-B的E3 连接酶活性，以增强肿瘤免 …
Nurix Announces Initial NX-1607 Phase 1 Data Presented at the …
2022年11月10日 · NX-1607 acts on T cells, NK cells, and dendritic cells to enhance anti-tumor immunity, and has demonstrated single-agent anti-tumor activity in multiple tumor models. …
AACR 2021：NX-1607治疗结直肠癌和三阴性乳腺癌，临床前研究效果显著 …
NX-1607是口服可生物利用的Casitas B谱系 淋巴瘤 B（CBL-B）的小分子抑制剂，在 结直肠癌 和三阴性 乳腺癌 的动物模型中均显示出显著的抗肿瘤功效。 重要的是，与任何一种单独的药物 …
In NK cells, CBL-B functions downstream of TAM receptors and negatively regulates cytokine production and cytotoxicity. Here, we characterized the antitumor and immune effects of NX …
824 NX-1607, a small molecule inhibitor of the CBL-B E3 ubiquitin ...
Combination of NX-1607 and Rituximab significantly enhanced tumor growth inhibition and stable rejections when compared to single agent activity. Importantly, the survival benefit provided by …
- 某些结果已被删除